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Redox rescues virus from ER trap
Abstract
How viruses manage to resist physical and chemical stress and yet open their protective coats during cell
infection has been a longstanding, fundamental question. A study with the DNA tumour virus SV40
now shows that protein folding and quality-control factors of the endoplasmic reticulum reshuffle
disulfide bonds within the viral capsid, providing a molecular mechanism for the exit of infectious
virions from the endoplasmic reticulum.
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How viruses manage to resist physical and chemical stress and yet open their protective coats 
during cell infection has been a longstanding, fundamental question. A study with the DNA 
tumour virus SV40 now shows that protein folding and quality-control factors of the 
endoplasmic reticulum reshuffle disulfide bonds within the viral capsid, providing a molecular 
mechanism for the exit of infectious virions from the endoplasmic reticulum. 
The concept of a viral replication cycle is exceedingly simple, yet its mechanisms hold many 
secrets. Upon engulfment of a virus by the host cell, uncoating of the viral genome from the 
protective capsid is required for the transcriptional activation of viral genes, using the transcriptional 
machinery of the host cell to drive the synthesis of viral progeny. Newly formed particles exit the 
cell, infect new cells, and the cycle starts again. On their way into a cell, animal viruses pass through 
cellular compartments where they encounter triggers that initiate viral coat destabilization. 
Examples of destabilization events include virus-receptor interactions, the shedding of minor capsid 
proteins, or the low pH in the digestive tract or in endosomal vesicles activating viral or cellular 
proteases that catalyse limited proteolysis1. In the past, therapeutic inhibition of uncoating has been 
a prominent strategy in the development of anti-viral drugs , particularly for non-enveloped viruses, 
such as picornaviruses2. Although in principle successful, the strategy has been largely abandoned 
 2 
due to the rapid appearance of viral escape mutants in patients treated with such antiviral drugs. 
Developing therapeutics directed against the host may be an interesting alternative. 
A recent paper by Schelhaas et al.3 reveals new host functions required for the infectious entry 
of the polyoma virus Simian Virus 40 (SV40). Polyoma viruses are non-enveloped DNA viruses that 
cause cancer in rodents and traces of their genome can be found in human tumours. Notably, SV40 
was accidentally inoculated into millions of humans during vaccinations with chemically-inactivated 
poliovirus in the 1950s when the vaccine virus was produced in SV40-infected monkey cells. The 
passage of SV40, mouse polyomavirus (mPy) and human BK virus into cells is intriguing, since 
these viruses use glycolipids as their cell attachment site4 (Fig.^1). Polyoma viruses are assembled 
in the nucleus under reducing conditions, and are oxidized outside the cell. The spatial separation of 
viral assembly and disassembly in part explains why a virus can be stably assembled in an infected 
cell, and disassembled on entry into a naïve cell5. 
The work by Schelhaas et al.3 shows how a virus uses the protein folding and quality-control 
apparatus for uncoating and membrane translocation. It provides a molecular explanation of two 
long standing observations, namely that the incoming SV40 is found in large amounts inside the ER6 
and that infectious particles are present in the cytosol7. The SV40 capsid has icosahedral symmetry 
and is composed of 72 homopentamers of the major capsid protein VP1. Twelve pentamers are five-
coordinated, the others are six-coordinated. It is unusually structured because the VP1 proteins are 
linked together via a network of interchain C9-C9 and C104-C104 disulfide bonds (Fig 1). The C-
terminal peptide of VP1 extends to binding sites on VP1 molecules of neighbouring pentamers that 
are stabilized by calcium ions8. In the life cycle of polyoma viruses, progeny capsids are assembled 
in the nucleus under reducing conditions and oxidized outside the cell. They do not come in contact 
with the enzymatic redox system in the ER, the site of viral uncoating. 
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The initial trigger for the research by Schelhaas et al. was the observation that in SDS 
polyacrylamide gels, treatment of non-reduced virus with alkylating agents yields VP1 multimers 
indicative of intersubunit disulfide bonds. These are not observed in the absence of alkylation, 
where free cysteines are available for  reshuffling the interchain disulfides of VP1. Moreover, 
alkylation of virus blocked infection and alkylated virus did not release VP1 during infection, 
indicative of a requirement for disulfide isomerisation rather than disulfide reduction for productive 
infection. Depletion of the two ER thiol–disulfide oxidoreductases ERp57 and the closely related 
protein disulfide isomerase (PDI) by small interfering RNA (siRNA) led to a significant reduction of 
infection, but only the depletion of ERp57 inhibited VP1 release in vivo, indicating that only ERp57 
resolves the interchain disulfide bonds. ERp57 is an essential soluble protein of the ER where it 
catalyses disulfide reduction, isomerization, and dithiol oxidation in substrate proteins. These 
findings are nicely complemented by an in vitro assay where both purified ERp57 and PDI were 
able to induce the loss of VP1 on isolated virus. To find out whether ERp57 and PDI serve as 
isomerase or reductase, alkylated (non-isomerizing) virus was used. Following treatment with 
ERp57, alkylated SV40 capsids did not release VP1 monomers although PDI was able to release 
VP1, suggesting that ERp57 acts as an isomerase and PDI acts as reductase. However, native SV40 
released VP1 following ERp57 treatment, supporting the siRNA knock down data. The disulfide 
isomerization activity of ERp57 is needed to resolve interchain disulfide bonds of the pentamers, 
yielding the intrachain disulfide bond C9–C104 (Fig.^1). Nevertheless, isomerization of  disulfide 
bonds is not sufficient for the dissociation of the pentamers; the loss of the VP1 associated Ca2+ ions 
is also required. Cryo-electron microscopy of partially uncoated viruses revealed that it was the five-
coordinated pentamers that were released, suggesting that they are less tightly associated than the 
six-coordinated pentamers. Interestingly, the C9–C104 disulfide bond is already in place in native 
mouse polyoma virus VP1 which has no interchain disulfide bonds and hence does not require the 
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Erp57 activity for infection9. The conformational changes around the SV40 VP1 disulfides weaken 
the capsid such that the myristoylated amino-terminal region of VP2 may swing out, and potentially 
positions the capsid to the lumenal face of the ER membrane. Electron micrographs suggest that 
SV40 is proximal to the lumenal ER membrane6. A similar principle of conformational change is 
used by mPy where in vitro experiments have shown that the thioredoxin-like Erp29 is required for 
membrane association of the virion9. 
But how is a nucleo-protein complex of 50^nm in diameter translocated through the ER 
membrane? The observation that proteasome inhibitors block SV40 entry suggests an involvement 
of ER-associated degradation (ERAD)3. ERAD requires chaperones that recognize misfolded 
proteins and the retrotranslocation machinery10. Cholera toxin, for example, requires reduced PDI 
for unfolding and presentation to the ERAD machinery. Accordingly, knockdown of PDI, Derlin-1 
and Sel1L reduced SV40 infection suggesting a role of ERAD in SV40 retrotranslocation. Derlin-1 
is a putative pore forming component, while Sel1L has been suggested to be required for substrate 
recognition. The sensor that recognizes the disulfide-reshuffled virus in the ER has not been 
identified, but may involve PDI or the signal peptide peptidase, perhaps recognizing VP210. This 
sensor may target the virus to the retrotranslocation complex. The rather low efficiency of SV40 
release from the ER into the cytosol (estimated to be1%) may explain why it remains unclear 
whether the translocated virus particles are ubiquitinated, a modification that normally occurs on 
proteins that are targeted to ERAD. Nevertheless, the translocated virus with isomerized disulfides 
sheds the VP1 pentamers in the low calcium conditions of the cytosol. This poises the particle for 
the release of infectious DNA into the nucleus, as shown for other DNA viruses11. 
One can speculate that the co-option of the ERAD machinery by SV40 occurs in conjunction 
with biosynthetic functions of the ER membranes, such as lipid synthesis, or lipid droplet 
formation12. Viral escape from the ER is, however, reminiscent of viral gene products that co-opt the 
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ERAD machinery to induce rapid degradation of host receptors or of immune surveillance 
molecules, such as MHC class I proteins10. The fact that the ER redox system contains more than 15 
different disulfide isomerases suggests that other viruses that visit the ER or interfere with ER 
functions, such as the papilloma viruses or picornaviruses, may use a similar pathway as SV40 — 
perhaps by engaging different isomerases. Future studies will uncover additional host factors and 
these may be useful targets for anti-viral therapies as they are not subject to viral resistance 
mutations. 
 
 
Figure^1 ERp57 and low calcium are involved in SV40 pentamer dissociation. (a)Infectious entry of SV40 
into human and monkey cells occurs via caveolin and lipid raft-dependent endocytosis on binding to the GM1 
ganglioside receptors at the plasma membrane13, 14. From the caveosome the viruses are transported inside 
vesicles along microtubules to the ER where they accumulate15. A cryo-electron microscopy  structure of 
intact SV40 capsids is shown in blue and reduced and calcium-depleted particles that release the pentavalent 
pentamers of the major capsid protein VP1 are in yellow3. The ER thiol-disulfide oxidoreductase ERp57 
isomerases SV40 interchain disulfide bonds. PDI, derlin-1 and Sel1L, three proteins involved in ER-
associated degradation (ERAD) are then thought to retrotranslocate particles to the cytosol where the low 
calcium concentration leads to pentamer dissociation. Cytosolic particles then enter the nucleus via the 
nuclear pore complex where viral transcription and replication takes place. (b)Model of SV40 disulfide 
isomerisation mediated by ERp57. Monomers of the major capsid protein VP1 of a five-coordinated 
pentamer (blue) are connected to neighboring six-coordinated pentamers (orange and green) via interchain 
disulfide bonds C9–C9 and C104–C104 (possible bonds are displayed by dashed lines). During disulfide 
bond isomerisation, the intrachain disulfide bond C9–C104 is formed for the VP1 molecule of the five-
coordinated pentamer and the six-coordinated pentamers are connected by a C104–C104 disulfide bond. This 
isomerisation reaction uncouples the five-coordinated pentamer from the disulfide bond network of the virus 
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capsid which may provide a signal for recognition of the particle by the ERAD machinery for translocation to 
the cytosol. 
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